ArticleBrain pathology (Zurich, Switzerland)2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
Article in Brain pathology (Zurich, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Pooled it
- AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for ependymomas.Brain pathology (Zurich, Switzerland) · 2026Article
- How is rosette formation in brain tumours linked with cerebrospinal fluid spread?Brain tumor pathology · 2026Review
- Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.Frontiers in oncology · 2026Article
- Current Approach and Predictors of Clinical Outcomes in Adults With Spinal Ependymomas.Cureus · 2025Article
- Supratentorial and Infratentorial Ependymoma.Advances and technical standards in neurosurgery · 2024Review
- Collision tumor comprised of chronic lymphocytic leukemia and myxopapillary ependymoma.Surgical neurology international · 2024Article
- Treatment Outcomes of Patients with Ependymoma Receiving Radiotherapy: A Single Institution Experience.Oncology · 2024Article
- Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022Review
- Development and validation of prognostic nomogram in ependymoma: A retrospective analysis of the SEER database.Cancer medicine · 2021Article
- Intracranial ependymomas: The role of advanced neuroimaging in diagnosis and management.The neuroradiology journal · 2021Review
- Personalizing age-specific survival prediction and risk stratification in intracranial grade II/III ependymoma.Cancer medicine · 2020Article
- Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing.F1000Research · 2019Article
- Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.Acta neuropathologica communications · 2018Article
- Outcome predictors in the management of intramedullary classic ependymoma: An integrative survival analysis.Medicine · 2018Observational
- C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.Journal of neuro-oncology · 2018Article
- EANO guidelines for the diagnosis and treatment of ependymal tumors.Neuro-oncology · 2018Review
- Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.Pathology oncology research : POR · 2017Article
- Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.Molecular neurobiology · 2017Review
- Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.Neuro-oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 13 institutions in 2 countries.
Funding
Abstract
Ependymomas originate in posterior fossa (PF), supratentorial (ST) or spinal cord (SC) compartments. At present, grading schemes are applied independent of anatomic site. We performed detailed histological examination on 238 World Health Organization grade II and III ependymomas. Among PF ependymomas, the presence of hypercellular areas, necrosis, microvascular proliferation and elevated mitotic rate (all P < 0.01) were significantly associated with worse progression-free survival (PFS), while extensive ependymal canal formation was not (P = 0.89). Similar to the PF tumors, microvascular proliferation (P = 0.01) and elevated mitotic rate (P = 0.03) were significantly associated with worse PFS in the ST tumors. However, in contrast to PF tumors, extensive ependymal canals (P = 0.03) were associated with worse clinical outcome in ST ependymomas, but hypercellularity (P = 0.57) and necrosis (P = 0.47) were not. On multivariate Cox regression, after adjusting for relevant clinical variables, individual histological factors and a composite histological score remained significant among ST and PF ependymoma. In contrast to both PF and ST ependymoma, histological features were not found to be associated with PFS in SC tumors. Taken together, the clinical relevance of specific histological features in ependymoma appears to be related to the anatomic site of origin and suggests that site-specific grading criteria be considered in future classification systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.